دورية أكاديمية
Humanistic and Economic Burden of Atopic Dermatitis for Adults and Adolescents in the Middle East and Africa Region.
العنوان: | Humanistic and Economic Burden of Atopic Dermatitis for Adults and Adolescents in the Middle East and Africa Region. |
---|---|
المؤلفون: | Elezbawy B; Syreon Middle East, 142 Elshaheed Galal Eldesouky Street, Alexandria, Egypt. baher.elezbawy@syreon.eu., Fasseeh AN; Syreon Middle East, 142 Elshaheed Galal Eldesouky Street, Alexandria, Egypt., Fouly E; Syreon Middle East, Dubai, United Arab Emirates., Tannira M; AbbVie BioPharmaceuticals, Dubai, United Arab Emirates., Dalle H; AbbVie BioPharmaceuticals, Kuwait City, Kuwait., Aderian S; AbbVie BioPharmaceuticals, Beirut, Lebanon., Abu Esba LC; Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, King Abdul Aziz Medical City, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Pharmacy, King Saud Bin Abdul Aziz University for Health Sciences, Riyadh, Saudi Arabia., Al Abdulkarim H; Drug Policy and Economic Center, Ministry of National Guard-Health Affairs, King Abdul Aziz Medical City, Riyadh, Saudi Arabia., Ammoury A; St George's University Medical Center, Beirut, Lebanon., Altawil E; Clinical Pharmacy Department, King Saud University Medical City, Riyadh, Saudi Arabia., Al Turaiki A; Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, King Abdul Aziz Medical City, Riyadh, Saudi Arabia., Albreiki F; Department of Dermatology, Tawam Hospital, Al Ain, United Arab Emirates., Al-Haddab M; Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia., Al-Lafi A; Department of Dermatology, As'ad Al Hamad Dermatology Centre, Shuwaikh Medical, Kuwait City, Kuwait., Alowayesh M; Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait., Al-Sheikh A; Dermatology Department, Ministry of National Guard-Health Affairs, King Abdul Aziz Medical City, Riyadh, Saudi Arabia., Elsayed M; Ain Shams University, Cairo, Egypt., Elshamy A; Wellbeing Office, Public Health Sector, Ministry of Health and Prevention, Dubai, United Arab Emirates., Eshmawi M; King Abdullah Medical Complex, Jeddah, Saudi Arabia., Farag A; Ain Shams University, Cairo, Egypt., Hamadah I; King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia., Hedibel M; Faculty of Pharmacy, University of Algiers, Algiers, Algeria., Kannenberg S; Stellenbosch University, Cape Town, South Africa., Karam R; Faculty of Sciences and Medical Sciences, Lebanese University, Beirut, Lebanon., Metni M; Faculty of Sciences, Lebanese University, Beirut, Lebanon., Raboobee N; Westville Hospital, Durban, South Africa., Steinhoff M; Hamad Medical Corporation, Doha, Qatar.; Department of Dermatology, Weill Cornell Medicine, New York, USA., Abaza S; Syreon Middle East, Cairo, Egypt., Farghaly M; Insurance Medical Regulation, Dubai Health Authority, Dubai, United Arab Emirates., Kaló Z; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.; Syreon Research Institute, Budapest, Hungary. |
المصدر: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2023 Jan; Vol. 13 (1), pp. 131-146. Date of Electronic Publication: 2022 Nov 29. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Publication: Switzerland : Springer Healthcare Communications Original Publication: Heidelberg : Springer 2011- |
مستخلص: | Introduction: Atopic dermatitis (AD) is a chronic skin disease that poses a significant burden on both patients and the society. AD causes the highest loss in disability-adjusted life years compared with other skin diseases. This study aimed to estimate the economic and humanistic burden of AD in adults and adolescents in seven countries in the Middle East and Africa region (Egypt, Lebanon, Saudi Arabia, Kuwait, Algeria, South Africa, and United Arab Emirates). Methods: We conducted a literature review to identify country-specific data on this disease. Subsequently, meetings were organized with experts from each country to complete the missing data. The data were aggregated and calculation models were created to estimate the value of the humanistic and economic burden of the disease in each country. Finally, we conducted meetings with local experts to validate the results, and the necessary adjustments were made. Results: On average, a patient with AD loses 0.19 quality-adjusted life years (QALYs) annually owing to this disease. The average annual healthcare cost per patient is highest in the United Arab Emirates, with an estimated value of US $3569 and a population-level indirect cost of US $112.5 million. The included countries allocated a range of 0.20-0.77% of their healthcare expenditure to AD-related healthcare services and technologies. The indirect cost of AD represents approximately 67% of the total disease cost and, on average, approximately 0.043% (range 0.022-0.059%) of the gross domestic product (GDP) of each country. Conclusion: Although the humanistic and economic burdens differ from country to country, AD carries a significant socioeconomic burden in all countries. The quality of life is severely affected by the disease. If AD is controlled, the costs, especially indirect costs, could decrease and the disease burden could be alleviated significantly. (© 2022. The Author(s).) |
References: | Talamonti M, Galluzzo M, Silvaggio D, Lombardo P, Tartaglia C, Bianchi L. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med Res. 2021;10(6):1298. https://doi.org/10.3390/jcm10061298 . (PMID: 10.3390/jcm10061298) Toron F, Neary MP, Smith TW, Gruben D, Romero W, Cha A, et al. Clinical and economic burden of mild-to-moderate atopic dermatitis in the UK: a propensity-score-matched case-control study. Dermatol Ther. 2021;11(3):907–28. https://doi.org/10.1007/s13555-021-00519-7 . (PMID: 10.1007/s13555-021-00519-7) Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93. https://doi.org/10.1111/all.13401 . (PMID: 10.1111/all.13401) Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(P3):340–7. https://doi.org/10.1016/j.anai.2018.07.006 . (PMID: 10.1016/j.anai.2018.07.006) Ariëns LF, Van Nimwegen KJ, Shams M, de Bruin DT, Van der Schaft J, Van Os-Medendorp H, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9):762–8. https://doi.org/10.2340/00015555-3212 . (PMID: 10.2340/00015555-3212) Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–9. https://doi.org/10.1111/bjd.19580 . (PMID: 10.1111/bjd.19580) Howe, W. Treatment of atopic dermatitis (eczema). 2021. https://www.uptodate.com/contents/treatment-of-atopic-dermatitis-eczema#:~:text=Topical%20corticosteroids%20%E2%80%94%20For%20patients%20with,for%20two%20to%20four%20weeks/ . Accessed 17 Dec 2021. Druss BG, Rosenheck RA, Sledge WH. Health and disability costs of depressive illness in a major US corporation. Am J Psychiatry. 2000;157(8):1274–8. https://doi.org/10.1176/appi.ajp.157.8.1274 . (PMID: 10.1176/appi.ajp.157.8.1274) Ibekwe PU, Ukonu BA. Impact of weather conditions on atopic dermatitis prevalence in Abuja, Nigeria. J Natl Med Assoc. 2019;111(1):88–93. https://doi.org/10.1016/j.jnma.2018.06.005 . (PMID: 10.1016/j.jnma.2018.06.005) Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol. 2013;133(7):1752–9. https://doi.org/10.1038/jid.2013.19 . (PMID: 10.1038/jid.2013.19) Al-Afif KAM, Buraik MA, Buddenkotte J, Mounir M, Gerber R, Ahmed HM, et al. Understanding the burden of atopic dermatitis in Africa and the Middle East. Dermatol Ther. 2019;9(2):223–41. https://doi.org/10.1007/s13555-019-0285-2 . (PMID: 10.1007/s13555-019-0285-2) Alqahtani JM. Atopy and allergic diseases among Saudi young adults: a cross-sectional study. J Int Med Res. 2020;48(1):0300060519899760. https://doi.org/10.1177/0300060519899760 . (PMID: 10.1177/0300060519899760) Hossny E, Shousha G, Wassif GO, Hana S. A study of health-related quality of life in pediatric atopic dermatitis. Egypt J Pediatr Allergy Immunol. 2020;18(2):61–9. https://doi.org/10.21608/ejpa.2020.117838 . (PMID: 10.21608/ejpa.2020.117838) Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9 . (PMID: 10.1016/S0140-6736(20)30925-9) Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279–86. https://doi.org/10.1007/s00403-013-1402-1 . (PMID: 10.1007/s00403-013-1402-1) Andersen L, Nyeland ME, Nyberg F. Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the USA. Br J Dermatol. 2020;182(5):1176–83. https://doi.org/10.1111/bjd.1845 . (PMID: 10.1111/bjd.1845) Le PH, Vo TQ, Nguyen NH. Quality of life measurement alteration among Vietnamese: impact and treatment benefit related to eczema. J Pak Med Assoc. 2019;69(suppl 2):S49–56. Lee SH, Lee SH, Lee SY, Lee B, Lee S, Park YL. Psychological health status and health-related quality of life in adults with atopic dermatitis: a nationwide cross-sectional study in South Korea. Acta Derm Venereol. 2018;98(1):89–97. https://doi.org/10.2340/00015555-2797 . (PMID: 10.2340/00015555-2797) Misery L, Seneschal J, Reguiai Z, Merhand S, Héas S, Huet F, et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol. 2019;33(2):428–32. https://doi.org/10.1111/jdv.15223 . (PMID: 10.1111/jdv.15223) Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290–300. https://doi.org/10.1111/1346-8138.14787 . (PMID: 10.1111/1346-8138.14787) Ezzedine K, Shourick J, Merhand S, Sampogna F, Taïeb C. Impact of atopic dermatitis in adolescents and their parents: a French study. Acta Derm Venereol. 2020;100:00015555–23653. https://doi.org/10.2340/00015555-3653 . (PMID: 10.2340/00015555-3653) DLQI to EQ-5D tool. Broadstreetheor.com. 2014. https://dlqi.broadstreetheor.com/ . Accessed 23 Aug 2021. Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205–16. https://doi.org/10.1007/s10198-018-0955-5 . (PMID: 10.1007/s10198-018-0955-5) World Health Organization. Global Health Expenditure Database. 2018. https://apps.who.int/nha/database/Select/Indicators/en/ . Accessed 20 Sep 2021. Worldbank.org. Official exchange rate (LCU per US$, period average) | Data. 2021. https://data.worldbank.org/indicator/PA.NUS.FCRF . Accessed 14 Sep 2021. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82–91. https://doi.org/10.2310/6620.2007.06034 . (PMID: 10.2310/6620.2007.06034) Mitchell RJ, Bates P. Measuring health-related productivity loss. Popul Health Manag. 2011;14(2):93–8. https://doi.org/10.1089/pop.2010.0014 . (PMID: 10.1089/pop.2010.0014) Country Profiles. ILOSTAT. 2020. https://ilostat.ilo.org/data/country-profiles/ . Accessed 31 Oct 2021. General Authority of Statistics-Kingdom of Saudi Arabia. Labor Force. 2020 https://www.stats.gov.sa/en/814/ . Accessed 24 Aug 2021. Africa S. More people participate in the South African labor market in the 4th quarter of 2020 | Statistics South Africa. Statssa.gov.za. 2021. http://www.statssa.gov.za/?p=14031#:~:text=The%20unemployment%20rate%20increased%20from,of%20the%20QLFS%20in%202008/ . Accessed 20 Sep 2021. The Complete Guide. Salaryexplorer.com. Average Salary in Lebanon 2021. 2021. http://www.salaryexplorer.com/salary-survey.php?loc=119&loctype=1/ . Accessed 20 Sep 2021. Francis A, Didsbury MS, Van Zwieten A, Chen K, James LJ, Kim S, et al. Quality of life of children and adolescents with chronic kidney disease: a cross-sectional study. Arch Dis Child. 2019;104:134–40. https://doi.org/10.1136/archdischild-2018-314934 . (PMID: 10.1136/archdischild-2018-314934) Federal Statistical Office. Health expenditure by functions of health care. 2019. https://www.destatis.de/EN/Themes/Society-Environment/Health/Health-Expenditure/Tables/functions.html;jsessionid=748464D51403C94AD92824D49D338E4B.live741 . Accessed 19 Oct 2021. Global Health Data Exchange. GBD Results Tool| GHDx. 2021. http://ghdx.healthdata.org/gbd-results-tool/ . Accessed 20 Aug 2021. |
فهرسة مساهمة: | Keywords: Africa; Atopic dermatitis; Disease burden; Economic burden; Eczema; Humanistic burden; Middle East; Quality of life Local Abstract: [plain-language-summary] Atopic dermatitis is a chronic condition characterized by inflamed and itchy skin. The prevalence and symptoms of atopic dermatitis are observed to increase in dry weather. Owing to its high prevalence in children, the majority of studies on atopic dermatitis are in children. Although it is also prevalent in adults and adolescents, its burden on adults has not been sufficiently studied, especially in Africa and the Middle East. This study quantified the burden of atopic dermatitis in adults and adolescents in seven countries in the Middle East and Africa. We estimated the economic and humanistic burden of this disease. We conducted a literature review and expert interviews to determine the effects on patients and caregivers. We created mathematical models to calculate the disease burden in each country, and local experts in each country validated the data. The study results showed that atopic dermatitis significantly affects the quality of life of patients. The direct medical costs of treatment in each country were calculated. The management of atopic dermatitis consumes around 0.20–0.77% of the healthcare expenditure in a country. The indirect cost of atopic dermatitis represents 0.022–0.059% of the gross domestic product (GDP) of a country. The country-specific burden data are essential to guide decision-makers in arriving at evidence-based decisions and efficiently allocating available resources. This study focused on the significant indirect economic burden of the disease, which can sometimes be underestimated because the disease is not fatal. |
تواريخ الأحداث: | Date Created: 20221129 Latest Revision: 20230201 |
رمز التحديث: | 20230202 |
مُعرف محوري في PubMed: | PMC9823172 |
DOI: | 10.1007/s13555-022-00857-0 |
PMID: | 36445612 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!